Teva Pharmaceutical Industries Ltd. (NYSE AND TASE: TEVA) Makes an “Innovation and Day of Pray”, where it is mentioned the future of biopharmautical activity. The company sees income from three leading medicines: AUSDEDO, for treating unintentional moves; The control of migraine ajovy movement; and long-term movement of schizophrenia Uzedy, reaching at least $ 5 billion in 2030. It is compared to $ 2 billion for three products combined with 2024.
The company confirms its guidance for 2027. It expects an operating margin of 30%, which prompts new quarters and the repair of occupation of $ 700 million. Free cash flows are expected to reach $ 2.7 billion 2027 and $ 3.5 billion in 2030.
Uri Herhskovitz, Hedge Ponda Pharma manager and a long-term analyst in Teva, says that guidance is strength, and the market has developed it, with pricing growth of the past five sessions. Today, the stock closed 1.57%. The company has a market cap over $ 20 billion.
Teva CEO Richard Francis says that the company increases $ 1 billion to the revenue income of two years from the pole of glass dedicated to Austeve. According to the company, this product will reach income of $ 2.5 billion 2027 and $ 3 billion in 2030. Teva’s guidance is mostly based on this product.
Francis added that when he arrived in Teva he heard the market doubts about the company’s ability to return to the new leadership. Since then, he said, a new product, Uzedy, launched, and positive results were taken with advanced clinical trials of two more products.
Teva Plan to submit a Second Long-Acting Treatment of Schizophrenia, Olanzapine, for the development of US development at 2025. Dari, a Dual-Action Rescue Rescue for about $ 1 Billion.
Emrolmin, described by Teva “a potential first-in-class treatment for many celiac disability appeals to FDA’s FDA Orse in FDAACS in FDAAs to FDAA
Related articles
Francis said there was a launch after launch, not only five plans, but in five drugs, some for many signs. He said the potential is better than this view, and is worth $ 10 billion, even if he added that there are no more extent expiries on the horizon. In winnings, the potential for launching five new biosimilar products in 2027, in addition to the past ten and past.
Published in Globes, Israel News in News – en.globes.co.il – On May 29, 2025.
© Copyright in Globes Publisher Itonut (1983) Ltd., 2025.
